Figura 1. Percentuale di pazienti che hanno raggiunto una settimana di buon controllo (non cumulativa) nelle settimane da - 4 a 52. Dato ottenuto per tutti gli strati combinati in trattamento con salmeterolo/fluticasone propionato e fluticasone propionato.(6)
Bibliografia
1. Kretchy IA, Asiedu-Danso M, Kretchy JP. Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from LMICs. Research in Social & Administrative Pharmacy 2020; doi: https://doi.org/10.1016/j.sapharm.2020.04.007.
2. Osterberg L and Blaschke T. Adherence to Medication. N Engl J Med 2005; 353:487-97.
3. Chrystyn H et al. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Primary Care Respiratory Journal 2009; 18(4):243-249.
4. COVID-19: GINA Answers to Frequently Asked Questions on Asthma Management. Release date: March 25, 2020 (www.ginasthma.org).
5. Lundback B et al. Asthma control over 3 years in a real-life study. Respiratory Medicine 2009; 103, 348-355.
6. Bateman ED et al. Can Guideline-defined Asthma Control Be Achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004; 170:836-844.